Views

CrossRef citations to date

Altmetric

Original Article

An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes

Philip HomeThe Medical School, Newcastle University, Newcastle upon Tyne, UKCorrespondence[email protected]

Sei Hyun BaikDivision of Endocrinology, Korea University Guro Hospital, Seoul, South Korea

Guillermo González GálvezInstituto Jalisciense de Investigación en Diabetes y Obesidad, Guadalajara, Mexico

Rachid MalekInternal Medicine Department, University Hospital Setif, Setif, Algeria

Annie NikolajsenMarket Access – Value Communication, Novo Nordisk A/S, Søborg, Denmark

Figures & data

Table 1. Baseline demographics and the change in clinical outcomes after 24 weeks from the A₁chieve study in people with T2D starting insulin detemir.

Download CSV Display Table

Table 2. Cumulative incidence and estimated time alive and free of complications (years) over 30 years after starting insulin detemir compared with not starting the insulin in people with T2D inadequately controlled on OGLDs.

Download CSV Display Table

Table 3. Direct costs per patient of diabetes care simulated over 30 years with insulin detemir compared with OGLDs alone.

Download CSV Display Table

Table 4. Long-term and short-term cost-effectiveness of starting insulin detemir in people with T2D inadequately controlled on OGLDs. Costs expressed per patient.

Download CSV Display Table

Table 5. Sensitivity analysis of starting insulin detemir in people with T2D inadequately controlled on OGLDs.

Download CSV Display Table

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes

Table 1. Baseline demographics and the change in clinical outcomes after 24 weeks from the A₁chieve study in people with T2D starting insulin detemir.

Table 2. Cumulative incidence and estimated time alive and free of complications (years) over 30 years after starting insulin detemir compared with not starting the insulin in people with T2D inadequately controlled on OGLDs.

Table 3. Direct costs per patient of diabetes care simulated over 30 years with insulin detemir compared with OGLDs alone.

Table 4. Long-term and short-term cost-effectiveness of starting insulin detemir in people with T2D inadequately controlled on OGLDs. Costs expressed per patient.

Table 5. Sensitivity analysis of starting insulin detemir in people with T2D inadequately controlled on OGLDs.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes

Figures & data

Table 1. Baseline demographics and the change in clinical outcomes after 24 weeks from the A1chieve study in people with T2D starting insulin detemir.

Table 2. Cumulative incidence and estimated time alive and free of complications (years) over 30 years after starting insulin detemir compared with not starting the insulin in people with T2D inadequately controlled on OGLDs.

Table 3. Direct costs per patient of diabetes care simulated over 30 years with insulin detemir compared with OGLDs alone.

Table 4. Long-term and short-term cost-effectiveness of starting insulin detemir in people with T2D inadequately controlled on OGLDs. Costs expressed per patient.

Table 5. Sensitivity analysis of starting insulin detemir in people with T2D inadequately controlled on OGLDs.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1. Baseline demographics and the change in clinical outcomes after 24 weeks from the A₁chieve study in people with T2D starting insulin detemir.